CTI Biopharma
Acquired
Developing novel therapies for rare blood-related cancers
- Employees
- 51–200
- Founded
- 1991
- Business Model
- B2B
- Website
- ctibiopharma.com
About
CTI BioPharma Corp was a biopharmaceutical company focused on acquiring, developing, and commercializing novel targeted therapies for blood-related cancers with unmet medical needs. The company's primary commercial product was Vonjo (pacritinib), approved by the FDA in 2022 for the treatment of adults with intermediate or high-risk myelofibrosis. Founded in 1991 and headquartered in Seattle, Washington, CTI BioPharma was listed on NASDAQ (CTIC) until its acquisition by Swedish Orphan Biovitrum AB (Sobi) in June 2023 for approximately $1.7 billion.